Walmart (WMT) Hit by New Children Safety Product Recalls
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Protective Packaging
E-commerce company iHerb has issued the urgent recall of around 60,000 units of Daily Prenatal Multi, Ultamins Women's Multivitamin, and Ultamins Women's 50+ Multivitamin.
The affected products should have had child-resistant packaging as required by the Poison Prevention Packaging Act. Because they were not child-resistant, each bottle posed serious harm to young children.
The units were sold at retailers from January 2019 through April 2025, costing between $8 and $18.
iHerb is advising customers to discard or return the vitamins for a full refund. Thankfully, it has not reported any illnesses or deaths related to the recalled products.
Recall Record
In addition, the Consumer Product Safety Commission has warned consumers to immediately stop using AIRLYA-Life Infant Walkers due to the risk of serious injury or death from fall and entrapment hazards.
There have been a number of product and food recalls at Walmart so far this year.
In April, Walmart recalled celery sticks because of a potential listeria contamination. That was also found during random sampling by the Georgia Department of Agriculture.
The month before, the US Food and Drug Administration (FDA) labeled broccoli sold in bags at Walmart stores as 'deadly' due to potential listeria contamination.
Is WMT a Good Stock to Buy Now?
On TipRanks, WMT has a Strong Buy consensus based on 29 Buy and 1 Hold ratings. Its highest price target is $120. WMT stock's consensus price target is $110.42 implying a 12.25% upside.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
a day ago
- Business Insider
Leerink Partners Remains a Buy on Ardent Health Partners, Inc. (ARDT)
Leerink Partners analyst Whit Mayo reiterated a Buy rating on Ardent Health Partners, Inc. yesterday. The company's shares closed last Thursday at $13.39. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, Tenet Healthcare, and UnitedHealth. According to TipRanks, Mayo has an average return of 2.7% and a 49.39% success rate on recommended stocks. Ardent Health Partners, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $21.17, a 58.10% upside from current levels. In a report released on June 20, KeyBanc also maintained a Buy rating on the stock with a $24.00 price target.
Business Insider
a day ago
- Business Insider
Leerink Partners Keeps Their Buy Rating on Universal Health (UHS)
In a report released yesterday, Whit Mayo from Leerink Partners reiterated a Buy rating on Universal Health. The company's shares closed last Thursday at $184.53. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, UnitedHealth, and HCA Healthcare. According to TipRanks, Mayo has an average return of 2.7% and a 49.39% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Universal Health with a $229.09 average price target, implying a 24.15% upside from current levels. In a report released on June 24, Barclays also maintained a Buy rating on the stock with a $257.00 price target. Based on Universal Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.1 billion and a net profit of $316.68 million. In comparison, last year the company earned a revenue of $3.84 billion and had a net profit of $261.83 million Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UHS in relation to earlier this year. Most recently, in May 2025, Maria Singer Ruderman, a Director at UHS sold 1,097.00 shares for a total of $210,042.59.
Business Insider
a day ago
- Business Insider
Leerink Partners Keeps Their Buy Rating on HCA Healthcare (HCA)
Leerink Partners analyst Whit Mayo reiterated a Buy rating on HCA Healthcare yesterday. The company's shares closed last Thursday at $376.58. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, UnitedHealth, and HCA Healthcare. According to TipRanks, Mayo has an average return of 2.7% and a 49.39% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HCA Healthcare with a $392.18 average price target, a 4.14% upside from current levels. In a report released on July 2, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $444.00 price target. HCA market cap is currently $90.6B and has a P/E ratio of 16.73. Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Most recently, in May 2025, Jon Foster, the EVP & COO of HCA sold 15,698.00 shares for a total of $5,797,585.36.
